Spectranetics extends laser to peripheral use:
This article was originally published in Clinica
Spectranetics plans to begin trials of its minimally-invasive laser for treating blocked arteries in the legs. The FDA told the company it could begin a ten-centre trial of the treatment, called peripheral excimer laser angioplasty, if it used a revised protocol based on the trials it undertook to gain approval in Europe. The treatment uses fibre optics to deliver short bursts of laser energy to dissolve blockages. Spectranetics, based in Colorado Springs, Colorado, already markets the CVX-300 excimer laser for cardiac procedures.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.